Purpose: We investigated the effects of the anti-epilepsy drug valproic acid (VPA) alone and in combination in treating cervical cancer.
Methods: VPA was investigated for its effects on cervical cancer Hela cell proliferation and tumor growth via in vitro and in vivo assays.
Results: VPA induce cell growth suppression and cell cycle arrest, with an increase of Notch1 that acts as a tumor suppressor and the change of other tumor-associated genes such as p21, p63 and PCNA. VPA was also found to induce cell morphological change, with an increase of certain cell transformation markers such as snail1, snail2 and N-cadherin. Moreover, VPA could significantly up-regulate somatostatin receptor type II (SSTR2). Our in vivo study further demonstrated that VPA via inducing SSTR2 up-regulation extremely enhanced the anti-tumor ability of the SSTR2-preferential cytotoxic COL-SST conjugate in xenografts.
Conclusions: VPA could not only suppress tumor progression but also provide a novel promising therapeutic choice in combination with a receptor-targeted cytotoxic conjugate via activating the specific receptor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00404-013-2762-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Valproic Acid Embryonic Exposure on Zebrafish: A Systematic Review and Meta-Analysis.
NeuroSci
December 2024
Instituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91070, Mexico.
Exposure to valproic acid (VPA) during embryogenesis has become a valuable tool for modeling neurodevelopmental disorders in animal models such as zebrafish (). This article examines the effects of embryonic exposure to VPA in zebrafish on the basis of 39 articles sourced from PubMed and Google Scholar. We conducted a systematic review and meta-analysis to elucidate the common impacts of VPA exposure and reported that VPA significantly altered development at various levels.
View Article and Find Full Text PDFAnatomical, behavioral, and cognitive teratogenicity associated with valproic acid: a systematic review.
CNS Spectr
December 2024
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Background: Recent guidance from UK health authorities strongly cautions against the use of valproic acid (VPA) in persons under 55 because of reevaluated risk of teratogenicity.
Objective: To summarize the extant literature documenting VPA-associated anatomical, behavioral, and cognitive teratogenicity.
Method: Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, Web of Science, and Google Scholar were searched in accordance with PRISMA guidelines.
Effects of Moringa oleifera extract on biochemical and histological parameters of sodium valproate induced lungs damage.
J Mol Histol
December 2024
Faculty of Engineering, Department of Chemistry, Istanbul University- Cerrahpaşa, Avcilar, Istanbul, Türkiye.
Sodium valproate- a salt of valproic acid (VPA), is an anticonvulsant used in the treatment of epilepsy and a range of psychiatric conditions that include panic attacks, anxiety, post-traumatic stress, migraine and bipolar disorder etc. VPA can cause direct damage to many tissues due to accumulation of toxic metabolites. Nowadays, phytochemicals are amongst the best options for the treatment of diseases.
View Article and Find Full Text PDFNeuroprotective effects of Apigenin on prenatal Valproic acid-induced autism spectrum disorder in rats.
IBRO Neurosci Rep
December 2024
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Unlabelled: Valproic acid (VPA) demonstrates teratogenic effects during pregnancy. Prenatal exposure to VPA may result in autism spectrum disorder (ASD) -like phenotypes. Apigenin, a natural flavonoid, has been shown to have neuroprotective impacts due to its antioxidant properties.
View Article and Find Full Text PDFThe Use of Perampanel in the Treatment of Lance-Adams Syndrome.
J Epilepsy Res
December 2024
Department of Neurology, Comprehensive Epilepsy Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lance Adams syndrome (LAS) is characterized by chronic action or intention myoclonus resulting from cerebral hypoxia. Perampanel, a non-competitive antagonist of aamino-3-hydroxy-5methyl-4 isooxazoleproprionic acid glutamate receptor, has demonstrated some efficacy in myoclonic epilepsy and other types of myoclonus. We report significant benefit in a patient with LAS treated with add on perampanel and provide a review of the relevant literature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!